Search

Your search keyword '"Wirth, Lori J."' showing total 9 results
Start Over Author "Wirth, Lori J." Journal cancer
9 results on '"Wirth, Lori J."'

1. Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial

Author

Kiyota, Naomi, primary, Tahara, Makoto, additional, Robinson, Bruce, additional, Schlumberger, Martin, additional, Sherman, Steven I., additional, Leboulleux, Sophie, additional, Lee, Eun Kyung, additional, Suzuki, Takuya, additional, Ren, Min, additional, Fushimi, Kazuma, additional, and Wirth, Lori J., additional

Published
2022
Full Text
View/download PDF

2. Cell‐free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancer

Author

O'Boyle, Connor J., primary, Siravegna, Giulia, additional, Varmeh, Shohreh, additional, Queenan, Natalia, additional, Michel, Alexa, additional, Pang, Kim Chang Sing, additional, Stein, Jarrod, additional, Thierauf, Julia C., additional, Sadow, Peter M., additional, Faquin, William C., additional, Wang, Wei, additional, Deschler, Daniel G., additional, Emerick, Kevin S., additional, Varvares, Mark A., additional, Park, Jong C., additional, Clark, John R., additional, Chan, Annie W., additional, Busse, Paul M., additional, Corcoran, Ryan B., additional, Wirth, Lori J., additional, Lin, Derrick T., additional, Iafrate, A. John, additional, Richmon, Jeremy D., additional, and Faden, Daniel L., additional

Published
2022
Full Text
View/download PDF

5. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)

Author

Wirth, Lori J., primary, Tahara, Makoto, additional, Robinson, Bruce, additional, Francis, Sanjeev, additional, Brose, Marcia S., additional, Habra, Mouhammed Amir, additional, Newbold, Kate, additional, Kiyota, Naomi, additional, Dutcus, Corina E., additional, Mathias, Elton, additional, Guo, Matthew, additional, Sherman, Steven I., additional, and Schlumberger, Martin, additional

Published
2018
Full Text
View/download PDF

6. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Author

Sherman, Steven I, Clary, Douglas O., Elisei, Rossella, Schlumberger, Martin J., Cohen, Ezra E. W., Schöffski, Patrick, Wirth, Lori J., Mangeshkar, Milan, Aftab, Dana T., and Brose, Marcia S.

Subjects
Cancer Research, Pyridines, Proto-Oncogene Proteins c-ret, cabozantinib, medullary thyroid cancer, RAS, RET, tyrosine kinase inhibitor, Anilides, Disease-Free Survival, Double-Blind Method, Humans, Mutation, Thyroid Neoplasms, ras Proteins, Oncology
Abstract

Cabozantinib significantly prolonged progression-free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P .001). An exploratory analysis of phase 3 trial data evaluated the influence of rearranged during transfection (RET) and RAS (HRAS, KRAS, and NRAS) mutations on cabozantinib clinical activity.Patients (n = 330) were randomized to cabozantinib (140 mg/day) or a placebo. The primary endpoint was PFS. Additional outcome measures included PFS, objective response rates (ORRs), and adverse events in RET and RAS mutation subgroups.Among all study patients, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P .0001), the RET mutation-unknown subgroup (HR, 0.30; 95% CI, 0.16-0.57; P = .0001), and the RAS mutation-positive subgroup (HR, 0.15; 95% CI, 0.02-1.10; P = .0317). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR, 0.15; 95% CI, 0.08-0.28; P .0001). The ORRs for RET mutation-positive, RET mutation-negative, and RAS mutation-positive patients were 32%, 22%, and 31%, respectively. No PFS benefit was observed in patients lacking both RET and RAS mutations, although the ORR was 21%. The safety profile for all subgroups was similar to that for the overall cabozantinib arm.These data suggest that cabozantinib provides the greatest clinical benefit to patients with MTC who have RET M918T or RAS mutations. However, a prospective trial is needed to confirm the relation between genetic variation and the response to cabozantinib. Cancer 2016;122:3856-3864. © 2016 American Cancer Society.

Published
2016

8. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Author

Jimeno, Antonio, primary, Posner, Marshall R., additional, Wirth, Lori J., additional, Saba, Nabil F., additional, Cohen, Roger B., additional, Popa, Elizabeta C., additional, Argiris, Athanassios, additional, Grossmann, Kenneth F., additional, Sukari, Ammar, additional, Wilson, Dawn, additional, Zhang, Xiaosha, additional, Sun, Jade, additional, Glasser, Chad, additional, Attie, Kenneth M., additional, Sherman, Matthew L., additional, Pandya, Susan S., additional, and Weiss, Jared, additional

Published
2016
Full Text
View/download PDF

9. Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Author

Sherman, Steven I., primary, Clary, Douglas O., additional, Elisei, Rossella, additional, Schlumberger, Martin J., additional, Cohen, Ezra E. W., additional, Schöffski, Patrick, additional, Wirth, Lori J., additional, Mangeshkar, Milan, additional, Aftab, Dana T., additional, and Brose, Marcia S., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results